Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Nivolumab and Relatlimab or Ipilimumab in Treating Patients with Locally Advanced, Unresectable, or Metastatic Melanoma

Melanoma

This phase II trial studies how well nivolumab given together with relatlimab or ipilimumab works in treating patients with melanoma that has spread to nearby tissue or lymph nodes (locally advanced), cannot be removed by surgery (unresectable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, relatlimab, and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Melanoma
II
Davis, Elizabeth
NCT03724968
VICCMEL18114

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: